Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells

Cancer Letters

Volumn 351, Issue 2, 2014, Pages 232-241

  Tian, Aiping ^a   Wilson, George S ^b   Lie, Stefanus ^b   Wu, Guang ^b   Hu, Zenan ^a   Hebbard, Lionel ^b   Duan, Wei ^c   George, Jacob ^b   Qiao, Liang ^b  

^a LANZHOU UNIVERSITY   (China)

^b UNIVERSITY OF SYDNEY   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

Combinatorial therapy; Hepatocellular carcinoma; JAK signalling; LCL161; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; LCL 161; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; INHIBITOR OF APOPTOSIS PROTEIN; N [1 CYCLOHEXYL 2 [2 [4 (4 FLUOROBENZOYL) 2 THIAZOLYL] 1 PYRROLIDINYL] 2 OXOETHYL] 2 (METHYLAMINO)PROPANAMIDE; THIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE ASSAY; CELL PROLIFERATION; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; CELL GROWTH; DRUG EFFECTS; GENETICS; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

INTRACISTERNAL A-PARTICLES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; THIAZOLES;

EID: 84904724381     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.06.006     Document Type: Article

References (34)

1. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
2. El-Serag H.B., Siegel A.B., Davila J.A., Shaib Y.H., Cayton-Woody M., McBride R., McGlynn K.A. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J. Hepatol. 2006, 44:158-166.
3. Parkin M.D. Global cancer statistics in the year 2000. Lancet Oncol. 2001, 2:533-543.
4. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
5. Simonetti R.G., Liberati A., Angiolini C., Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann. Oncol. 1997, 8:117-136.
6. Whittaker S. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29:4989-5005.
7. Cheng A.-L., Kang Y.-K., Chen Z., Tsao C.-J., Qin S., Kim J.S., Luo R., Feng J., Ye S., Yang T.-S., Xu J., Sun Y., Liang H., Liu J., Wang J., Tak W.Y., Pan H., Burock K., Zou J., Voliotis D., Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10:25-34.
8. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
9. Ebos J.M.L., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
10. Ebos J.M.L., Lee C.R., Kerbel R.S. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin. Cancer Res. 2009, 15:5020-5025.
11. Narayana A., Kelly P., Golfinos J., Parker E., Johnson G., Knopp E., Zagzag D., Fischer I., Raza S., Medabalmi P., Eagan P., Gruber M.L. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 2009, 110:173-180.
12. Norden A.D., Young G.S., Setayesh K., Muzikansky A., Klufas R., Ross G.L., Ciampa A.S., Ebbeling L.G., Levy B., Drappatz J., Kesari S., Wen P.Y. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70:779-787.
13. Liston P., Fong W.G., Korneluk R.G. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003, 22:8568-8580.
14. Yamaguchi Y., Shiraki K., Fuke H., Inoue T., Miyashita K., Yamanaka Y., Saitou Y., Sugimoto K., Nakano T. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol. Rep. 2005, 14:1311-1316.
15. Augello C., Caruso L., Maggioni M., Donadon M., Montorsi M., Santambrogio R., Torzilli G., Vaira V., Pellegrini C., Roncalli M., Coggi G., Bosari S. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 2009, 9:125-134.
16. Dai Y., Qiao L., Chan K.W., Yang M., Ye J., Ma J., Zou B., Gu Q., Wang J., Pang R., Lan H.Y., Wong B.C.Y. Peroxisome proliferator-activated receptor-γ contributes to the inhibitory effects of embelin on colon carcinogenesis. Cancer Res. 2009, 69:4776-4783.
17. Dai Y., Qiao L., Chan K.W., Yang M., Ye J., Zhang R., Ma J., Zou B., Lam C.S.C., Wang J., Pang R., Tan V.P.Y., Lan H.Y., Wong B.C.Y. Adenovirus-mediated down-regulation of X-linked inhibitor of apoptosis protein inhibits colon cancer. Mol. Cancer Ther. 2009, 8:2762-2770.
18. Ikeguchi M., Ueda T., Sakatani T., Hirooka Y., Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn. Mol. Pathol. 2002, 11:33-40.
19. Li Z., Chen J., Chan K.W., Qiao L., Wong B.C.Y. A possible role of cIAP2 in Helicobacter pylori-associated gastric cancer. Cancer Lett. 2011, 313:192-200.
20. Qiao L., Dai Y., Gu Q., Chan K.W., Zou B., Ma J., Wang J., Lan H.Y., Wong B.C.Y. Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor ligand-induced growth inhibition in colon cancer. Mol. Cancer Ther. 2008, 7:2203-2211.
21. Yu J., Qiao L., Zimmermann L., Ebert M.P.A., Zhang H., Lin W., Röcken C., Malfertheiner P., Farrell G.C. Troglitazone inhibits tumor growth in hepatocellular carcinomain vitroandin vivo. Hepatology 2006, 43:134-143.
22. Shiraki K., Sugimoto K., Yamanaka Y., Yamaguchi Y., Saitou Y., Ito K., Yamamoto N., Yamanaka T., Fujikawa K., Murata K., Nakano T. Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int. J. Mol. Med. 2003, 12:705-708.
23. McKinlay M.A. SMAC MIMETICS: a new class of targeted agents that activate apoptotic cell death and block pro-survival signalling in cancer cells. Drug Discovery World Fall 2011, 2011:37-41.
24. Pei Z., Chu L., Zou W., Zhang Z., Qiu S., Qi R., Gu J., Qian C., Liu X. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004, 39:1371-1381.
25. Li L., Thomas R.M., Suzuki H., De Brabander J.K., Wang X., Harran P.G. A small molecule Smac mimic potentiates TRAIL- and TNFa-mediated cell death. Science 2004, 305:1471-1474.
26. Oost T.K., Sun C., Armstrong R.C., Al-Assaad A.-S., Betz S.F., Deckwerth T.L., Ding H., Elmore S.W., Meadows R.P., Olejniczak E.T., Oleksijew A., Oltersdof T., Rosenberg S.H., Shoemaker A.R., Tomaselli K.J., Zou H., Fesik S.W. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. 2004, 47:4417-4426.
27. Arnt C.R., Chiorean M.V., Heldebrant M.P., Gores G.J., Kaufmann S.H. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. 2002, 277:44236-44243.
28. Dhuria S., Firestone B., Kappels D., Sager J., Spence S., Wood K., Zawel L. LCL161: Investigator's Brochure 2009, Novartis.
29. Fulda S., Wick W., Weller M., Debatin K.-M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 2002, 8:808-815.
30. Weisberg E., Ray A., Barrett R., Nelson E., Christie A.L., Porter D., Straub C., Zawel L., Daley J.F., Lazo-Kallanian S., Stone R.L., Galinsky I., Frank D., Griffin J.D. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 2010, 24:2100-2109.
31. Chen K.-F., Lin J.-P., Shiau C.-W., Tai W.-T., Liu C.-Y., Yu H.-C., Chen P.-J., Cheng A.-L. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Biochem. Pharmacol. 2012, 84:268-277.
32. Wilson G.S., Tian A., Hebbard L., Duan W., George J., Li X., Qiao L. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Lett. 2013, 341:224-230.
33. R. Dienstmann, L. Vidal, E. Dees, S. Chia, E. Mayer, D. Porter, T. Baney, S. Dhuria, S. Sen, B. Firestone, A Phase Ib study of LCL161, an oral inhibitor of apoptosis (IAP) antagonist, in combination with weekly paclitaxel in patients with advanced solid tumors, in: Poster Presented at 35th Annual Meeting of San Antonio Breast Cancer Symposium (SABCS), AACR, 2012.
34. LaCasse E.C., Mahoney D.J., Cheung H.H., Plenchette S., Baird S., Korneluk R.G. IAP-targeted therapies for cancer. Oncogene 2008, 27:6252-6275.